Ryan Rhodes, Chief Executive Officer at EDAP TMS SA (FOCL), bought 21,000 shares at $4.75 ($100K) on 2026-08-14, disclosed to the SEC on 2026-08-17.
EDAP TMS CEO Ryan Rhodes purchased $99,750 of stock at $4.75 per share, marking the largest purchase of his career and signaling confidence in the company's growth trajectory. The trade coincides with a period of strong operational performance and expanding market opportunities in HIFU technology.
The stock is currently trading at a forward P/E of -7.50, indicating a valuation that may not fully reflect the company's recent revenue growth. Recent news highlights a 39% surge in HIFU revenue for Q2 2026, driven by strong capital sales and procedure volume expansion.
1) Q2 2026 earnings call on August 14, 2026, which reported a 39% increase in HIFU revenue driven by strong capital sales and procedure volume growth. 2) Continued expansion into new indications such as benign prostatic hyperplasia and endometriosis, funded by recent equity raises. 3) Analyst price target revisions, with one report raising the fair value estimate from US$6.83 to US$8.50 on July 19, 2026.
1) The stock's forward P/E of -7.50 suggests potential overvaluation or market skepticism regarding future profitability. 2) Recent news indicates that earnings estimate revisions do not suggest further strength, which could limit upside if execution falters.
Something here stands out, but not much.